ArticleFrontiers in oncology2025

Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China.

Guangming Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.